You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
AMD 3465 hexahydrobromide
Biological Activity for AMD 3465 hexahydrobromide
AMD 3465 hexahydrobromide is a potent, selective CXCR4 antagonist; exhibits 8-fold higher affinity than AMD 3100 (Cat.No. 3299). Inhibits SDF-1α-ligand binding (Ki = 41.7 nM). Potently inhibits HIV cell entry in vitro; causes leukocytosis and mobilizes haematopoietic stem cells in vivo.
Compound Libraries for AMD 3465 hexahydrobromide
AMD 3465 hexahydrobromide is also offered as part of the Tocriscreen 2.0 Max, Tocriscreen Antiviral Library and Tocriscreen Stem Cell Library. Find out more about compound libraries available from Tocris.
Technical Data for AMD 3465 hexahydrobromide
|Storage||Store at -20°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Solubility Data for AMD 3465 hexahydrobromide
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions for AMD 3465 hexahydrobromide
The following data is based on the product molecular weight 896.07. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|0.5 mM||2.23 mL||11.16 mL||22.32 mL|
|2.5 mM||0.45 mL||2.23 mL||4.46 mL|
|5 mM||0.22 mL||1.12 mL||2.23 mL|
|25 mM||0.04 mL||0.22 mL||0.45 mL|
Product Datasheets for AMD 3465 hexahydrobromide
References for AMD 3465 hexahydrobromide
References are publications that support the biological activity of the product.
Rosenkilde et al (2007) Molecular mechanism of action of monocyclam versus bicyclam non-peptide antagonists of the CXCR4 chemokine receptor. J.Biol.Chem. 282 27354 PMID: 17599916
Bodart et al (2009) Pharmacology of AMD3465: A small molecule antagonist of the chemokine receptor CXCR4. Biochem.Pharmacol. 78 993 PMID: 19540208
If you know of a relevant reference for AMD 3465 hexahydrobromide, please let us know.
View Related Products by Product Action
Keywords: AMD 3465 hexahydrobromide, AMD 3465 hexahydrobromide supplier, AMD3465, CXCR4, receptor, antagonist, chemokine, chemokines, antagonists, Chemokine, CXC, Receptors, 4179, Tocris Bioscience
2 Citations for AMD 3465 hexahydrobromide
Citations are publications that use Tocris products. Selected citations for AMD 3465 hexahydrobromide include:
Luo et al (2016) Crosstalk between astrocytic CXCL12 and microglial CXCR4 contributes to the development of neuropathic pain. Mol Pain 12 PMID: 27030717
Lourenco et al (2015) Macrophage migration inhibitory factor-CXCR4 is the dominant chemotactic axis in human mesenchymal stem cell recruitment to tumors. J Immunol 194 3463 PMID: 25712213
Do you know of a great paper that uses AMD 3465 hexahydrobromide from Tocris? Please let us know.
Reviews for AMD 3465 hexahydrobromide
Average Rating: 4 (Based on 1 Review.)
Have you used AMD 3465 hexahydrobromide?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Receptor antagonists (SB225002: for CXCR2, AMD3465: for CXCR4, RS504393: for CCR2 and Maraviroc: for CCR5) at 10 μM
We ordered this product, combining with another inhibitor, to confirm the migration.To confirm that tested product induces migration, we also screen all MAPK inhibitors and MIF receptor antagonists
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Rheumatoid Arthritis Poster
Rheumatoid arthritis (RA) is a chronic destructive inflammatory autoimmune disease that results from a breakdown in immune tolerance, for reasons that are as yet unknown. This poster summarizes the pathology of RA and the inflammatory processes involved, as well as describing some of the epigenetic modifications associated with the disease and the potential for targeting these changes in the discovery of new treatments.